Sepsis and Septic Shock: From Molecular Mechanism to Novel Therapies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (15 July 2024) | Viewed by 716
Special Issue Editor
Special Issue Information
Dear Colleagues,
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection (either suspected or confirmed) and is a serious health issue with high morbidity and mortality despite years of research. There is still a lack of effective therapies apart from antibiotics and fluid resuscitation.
A better understanding of molecular mechanisms involved in sepsis can help identify new and specific biomarkers and targets for the diagnosis and treatment of sepsis. For example, histone, a DAMP released by NETosis and other cell death processes such as apoptosis, necroptosis, and pyroptosis, has been identified as having harmful effects in sepsis, including inducing endothelial dysfunction, coagulopathy, and barrier damage. New therapies are thus being developed to block histone signalling pathways or histone release and to neutralize its effects. A histone neutralization compound, mCBS, has been recently shown to have beneficial effects including decreased vasopressor use, reduced inflammation, and improved tissue perfusion in translational studies and ongoing clinical phase II efficacy trials.
This is a perfect example to show the link between molecular mechanisms and the development of novel therapies for sepsis. To shed more light on this field, we are launching a Special Issue "Sepsis and Septic Shock: From Molecular Mechanism to Novel Therapies". All studies and reviews related to sepsis mechanisms and therapeutic strategies are welcome.
Dr. Fuhong Su
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- sepsis
- septic shock
- molecular mechanisms
- specific biomarkers
- histone
